VIB305 not checked

Vibrant Sciences Limited

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
1 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Intravenous infusion: once every week/every two weeks/every three weeks, each treatment cycle is 3 weeks/4 weeks/6 weeks.”In the company’s words, NCT07222969 on ClinicalTrials.gov
Tested for
Advanced Solid Tumors
Main trialPhase 1/2
“This clinical trial is an open-label, single-arm, non-randomized, dose-escalation and dose-expansion study targeting subjects with unresectable, advanced, malignant solid tumors who have failed or are unsuitable for standard treatments. This study is divided into a dose-escalation phase (Phase I) and a dose-expansion phase (Phase II). Phase I (dose escalation) is designed to preliminarily evaluate the safety and tolerability, PK profile, preliminary antitumor activity and immunogenicity of VIB305 in advanced solid tumors, to determine the nature and incidence of dose-limiting toxicities…”In the company’s words, NCT07222969 on ClinicalTrials.gov

Other drugs for Advanced Solid Tumors

All 2439 drugs for Advanced Solid Tumors

Coming up1

Changes1

Last 90 days

Trials1

TrialPhaseCompletesWhat it tests
Phase 1/2Recruiting 30 Sep 2027 A Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026

Follow VIB305

Following is part of Solo: you see every change to VIB305 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in